» Articles » PMID: 34996922

Application of a Tungsten Apron for Occupational Radiation Exposure in Nursing Care of Children with Neuroblastoma During I-meta-iodo-benzyl-guanidine Therapy

Overview
Journal Sci Rep
Specialty Science
Date 2022 Jan 8
PMID 34996922
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

The use of effective shielding materials against radiation is important among medical staff in nuclear medicine. Hence, the current study investigated the shielding effects of a commercially available tungsten apron using gamma ray measuring instruments. Further, the occupational radiation exposure of nurses during I-meta-iodo-benzyl-guanidine (I-MIBG) therapy for children with high-risk neuroblastoma was evaluated. Attachable tungsten shields in commercial tungsten aprons were set on a surface-ray source with I, which emit gamma rays. The mean shielding rate value was 0.1 ± 0.006 for I. The shielding effects of tungsten and lead aprons were evaluated using a scintillation detector. The shielding effect rates of lead and tungsten aprons against I was 6.3% ± 0.3% and 42.1% ± 0.2% at 50 cm; 6.1% ± 0.5% and 43.3% ± 0.3% at 1 m; and 6.4% ± 0.9% and 42.6% ± 0.6% at 2 m, respectively. Next, we assessed the occupational radiation exposure during I-MIBG therapy (administration dose: 666 MBq/kg, median age: 4 years). The total occupational radiation exposure dose per patient care per I-MIBG therapy session among nurses was 0.12 ± 0.07 mSv. The average daily radiation exposure dose per patient care among nurses was 0.03 ± 0.03 mSv. Tungsten aprons had efficient shielding effects against gamma rays and would be beneficial to reduce radiation exposures per patient care per I-MIBG therapy session.

Citing Articles

Effectiveness of shielding materials against Lu gamma rays and the corresponding distance relationship.

Okuhata K, Monzen H, Nakamura Y, Takai G, Nagano K, Nakamura K Ann Nucl Med. 2023; 37(11):629-634.

PMID: 37596439 DOI: 10.1007/s12149-023-01860-x.

References
1.
Beck M . Radiation safety in the management of patients undergoing radioactive iodine ablation therapy. Clin J Oncol Nurs. 2015; 19(1):44-6. DOI: 10.1188/15.CJON.44-46. View

2.
Al-Mohammed H, Sulieman A, Mayhoub F, Salah H, Lagarde C, Alkhorayef M . Occupational exposure and radiobiological risk from thyroid radioiodine therapy in Saudi Arabia. Sci Rep. 2021; 11(1):14557. PMC: 8282852. DOI: 10.1038/s41598-021-93342-1. View

3.
Abualroos N, Azman M, Baharul Amin N, Zainon R . Tungsten-based material as promising new lead-free gamma radiation shielding material in nuclear medicine. Phys Med. 2020; 78:48-57. DOI: 10.1016/j.ejmp.2020.08.017. View

4.
Giammarile F, Chiti A, Lassmann M, Brans B, Flux G . EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy. Eur J Nucl Med Mol Imaging. 2008; 35(5):1039-47. DOI: 10.1007/s00259-008-0715-3. View

5.
Bayram T, Yilmaz A, Demir M, Sonmez B . Radiation dose to technologists per nuclear medicine examination and estimation of annual dose. J Nucl Med Technol. 2011; 39(1):55-9. DOI: 10.2967/jnmt.110.080358. View